Kapitalforeningen Accunia Invest
Udlodning for 4. kvartal 2020
Bestyrelsen i Kapitalforeningen Accunia Invest har godkendt nedennævnte udlodninger for fjerde kvartal af 2020. Udlodningerne vil formelt set blive endeligt godkendt på foreningens ordinære generalforsamling.
De optjente udbytter er vist i nedenstående tabel. Tallene er beregnet pr. 31. december 2020 og opgjort i kr. pr. investeringsbevis.
| ISIN | Kortnavn | Andelsklasse/afdeling | DKK/andel |
| DK0060804136 | ACACIGDKK | European CLO Investment Grade | 5 |
| DK0060804052 | ACAECO | European CLO Opportunity KL | 13 |
| DK0061149036 | ACKEHY | European High Yield KL | 15 |
Tidsplan
22. januar 2021 Sidste dag for handel med beviser inkl. udbytte for 4. kvartal 2020
25. januar 2021 Udbyttet fragår, og investeringsbeviserne handles uden udbytte for 4. kvartal 2020
27. januar 2021 Udbyttet er til disposition på investors konto
Kontaktperson(er):
Direktør Caspar Møller, tlf. +45 3332 7070.
Yderligere oplysninger om Kapitalforeningen Accunia Invest findes på www.accunia.com.
About Globenewswire
Subscribe to releases from Globenewswire
Subscribe to all the latest releases from Globenewswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Globenewswire
Synairgen plc25.1.2021 08:06:49 CET | Press release
Synairgen announces inclusion of its inhaled interferon beta treatment in US NIH ACTIV-2 trial in COVID-19 outpatients
F. Hoffmann-La Roche Ltd25.1.2021 08:06:08 CET | Press release
Roche renews partnership with Sysmex to deliver haematology testing solutions
Royal Philips25.1.2021 08:06:08 CET | Press release
Philips delivers Q4 sales of EUR 6.0 billion, with 7% comp. sales growth; income from cont. operations increases to EUR 608 million, Adjusted EBITA margin improves 110 bps to 19.0%, and operating cash flow increases to EUR 1,305 million
F. Hoffmann-La Roche Ltd25.1.2021 08:02:27 CET | Press release
Roche’s faricimab meets primary endpoint in two global phase III studies and shows potential to extend time between treatments up to 16 weeks for people with neovascular age-related macular degeneration
Junshi Biosciences25.1.2021 08:01:47 CET | Press release
FDA Grants Toripalimab Fast Track Designation for Mucosal Melanoma
Montreal Heart Institute23.1.2021 07:02:08 CET | Press release
Colchicine reduces the risk of COVID-19-related complications
Zealand Pharma22.1.2021 22:06:25 CET | Press release
Zealand Pharma announces update to 2020 financial guidance
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom